BR112016007664A2 - uso de n-(4-tert-butilbenzil)-3-cloro-n-[2-(4-cloro-3-etil-fenil)-etil-2-fluoro-5-trifluoroetil-benzamida para o tratamento de doenças no olho - Google Patents

uso de n-(4-tert-butilbenzil)-3-cloro-n-[2-(4-cloro-3-etil-fenil)-etil-2-fluoro-5-trifluoroetil-benzamida para o tratamento de doenças no olho

Info

Publication number
BR112016007664A2
BR112016007664A2 BR112016007664A BR112016007664A BR112016007664A2 BR 112016007664 A2 BR112016007664 A2 BR 112016007664A2 BR 112016007664 A BR112016007664 A BR 112016007664A BR 112016007664 A BR112016007664 A BR 112016007664A BR 112016007664 A2 BR112016007664 A2 BR 112016007664A2
Authority
BR
Brazil
Prior art keywords
ethyl
chloro
diseases
eye
benzamide
Prior art date
Application number
BR112016007664A
Other languages
English (en)
Inventor
Chaput Evelyne
Hartmann Guido
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016007664A2 publication Critical patent/BR112016007664A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1/1 resumo “uso de n-(4-tert-butilbenzil)-3-cloro-n-[2-(4cloro- 3-etil-fenil)-etil-2-fluoro-5-trifluoroetil-benzamida para o tratamento de doenças no olho” a presente invenção diz respeito a n-(4-tertbutil- benzil)-3-cloro-n-[2-(4-cloro-3-etil-fenil)-etil]-2fluoro- 5-trifluorometil-benzamida que é útil na prevenção, tratamento, atraso na progressão e/ou redução de doenças no olho, em particular em que as doenças do olho são doenças neovasculares intraoculares e seu método de prevenção, retardamento e melhoramento de doenças do olho, em particular doenças neovasculares intraoculares.
BR112016007664A 2013-10-08 2014-10-06 uso de n-(4-tert-butilbenzil)-3-cloro-n-[2-(4-cloro-3-etil-fenil)-etil-2-fluoro-5-trifluoroetil-benzamida para o tratamento de doenças no olho BR112016007664A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13187678 2013-10-08
PCT/EP2014/071280 WO2015052104A1 (en) 2013-10-08 2014-10-06 Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
BR112016007664A2 true BR112016007664A2 (pt) 2017-08-01

Family

ID=49303863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007664A BR112016007664A2 (pt) 2013-10-08 2014-10-06 uso de n-(4-tert-butilbenzil)-3-cloro-n-[2-(4-cloro-3-etil-fenil)-etil-2-fluoro-5-trifluoroetil-benzamida para o tratamento de doenças no olho

Country Status (11)

Country Link
US (1) US20170035708A1 (pt)
EP (1) EP3054979A1 (pt)
JP (1) JP2016532658A (pt)
KR (1) KR20160058835A (pt)
CN (1) CN105658239A (pt)
BR (1) BR112016007664A2 (pt)
CA (1) CA2922637A1 (pt)
HK (1) HK1220144A1 (pt)
MX (1) MX2016004410A (pt)
RU (1) RU2016114724A (pt)
WO (1) WO2015052104A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058750B2 (en) * 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
EP1471898B1 (en) * 2002-01-30 2008-01-02 DSM IP Assets B.V. Lutein/zeaxanthin for glare protection
US7923724B2 (en) * 2005-01-10 2011-04-12 Ovonyx, Inc. Phase change memory that switches between crystalline phases
US7745477B2 (en) * 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
JP2010509369A (ja) * 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド 加齢黄斑変性症を処置するための方法
US20110313196A1 (en) * 2010-06-18 2011-12-22 Stephan Bachmann Novel process
US20120301439A1 (en) * 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization

Also Published As

Publication number Publication date
HK1220144A1 (zh) 2017-04-28
WO2015052104A1 (en) 2015-04-16
US20170035708A1 (en) 2017-02-09
RU2016114724A3 (pt) 2018-07-13
KR20160058835A (ko) 2016-05-25
CA2922637A1 (en) 2015-04-16
JP2016532658A (ja) 2016-10-20
MX2016004410A (es) 2016-07-05
EP3054979A1 (en) 2016-08-17
CN105658239A (zh) 2016-06-08
RU2016114724A (ru) 2017-11-13

Similar Documents

Publication Publication Date Title
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
MD3302471T2 (ro) Compuși de alchenă tetrasubstituiți și utilizarea acestora
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112015013123A2 (pt) inibidores de beta-lactamase
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112017019971A2 (pt) exclusão de éxon induzida por anti-sentido em miostatina
EA201991650A1 (ru) Способы лечения неврологических расстройств
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112017025263A2 (pt) método para o tratamento de doença neurológica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements